PhytoMedical's Latest Anti-Cancer Compounds Kill Human Colon Cancer Cells
In important tests against a difficult-to-treat strain of human colon cancer cells (HCT116), scientists evaluated the performance of concentrated amounts of PhytoMedical's newest anti-cancer compounds. Researchers observed a 50% or greater cancer cell kill rate using these patented compounds, reporting excellent success in the Company's second phase tests where researchers have employed PhytoMedical's new, synthetic bis-acridines for the first time.
"Based on encouraging outcomes from early phase one research into our first-generation anti-cancer compounds, we immediately bolstered our efforts and initiated tests of our next-generation compounds. These phase two tests were specifically designed to target difficult-to-treat strains of human cancer cells, and the resulting outcomes have been very favorable," explained Mr. Greg Wujek, President and CEO of PhytoMedical Technologies, Inc.
"We're especially pleased to see that our newest compounds, which are modeled after our first-generation bis-acridines, have continued to remain effective at killing human glioblastoma cells related to brain cancer, while clearly demonstrating their newly-discovered ability to kill cells from human colon cancer, a deadly form of cancer which takes nearly 1,800 lives every single day."
Despite advances in surgery, chemotherapy, biological therapy, and radiation therapy, the need for a new, effective treatment able to kill colon cancer cells is clear. According to the World Health Organization, colon cancer - often referred to as, 'colorectal cancer' - accounts for an estimated 655,000 deaths per year, globally. In the United States, colorectal cancer is the fourth most common form of cancer, and was the second leading cause of cancer-related deaths last year (American Cancer Society, 2007).
PhytoMedical's Cancer Research: Killing Cancer's DNA
In collaboration with Dartmouth College and Dr. Gordon W. Gribble, PhytoMedical is developing a novel class of patented anti-cancer agents that have a 'cytotoxic' or poisonous affinity for cancer cells. These new compounds are designed to bind more tightly to cancer cell DNA than many conventional anticancer drugs by a process called bis-intercalation or "double binding," much like a molecular staple. Because the DNA is the blueprint of life for the cancer cell, such binding stops the replication of the DNA, which prevents the growth of the cancer cell and it dies.
DNA is present in the nucleus of every cell of all living organisms, which are constantly dividing through a process in which the DNA in the nucleus of the original cell replicates itself to be present in the nuclei of the two new ("daughter") cells. If this replication cannot occur, the cell will die and the organism will eventually stop growing and die. Cancer is characterized by the development of abnormal cells that divide uncontrollably and have the ability to infiltrate and destroy normal body tissue.
At present, anticancer molecules designed to block the replication of DNA do so through "intercalation," a mechanism in which the drug inserts itself between one set of adjacent base pairs of the DNA. PhytoMedical believes a more effective anticancer strategy is to design molecules ("bis-intercalators") that can intercalate simultaneously at two DNA sites, thus further increasing the binding between the drug and the DNA of specific cancer cells in order to stop their replication and ultimately resulting in the death of the cancer cell.
About PhytoMedical Technologies, Inc.
PhytoMedical Technologies, Inc. (OTCBB: PYTO; Frankfurt Stock Exchange: ET6), together with its wholly owned subsidiaries, is a pharmaceutical company focused on research, development and commercialization of pharmaceutical products.
For additional information, please visit http://www.PhytoMedical.com
Legal Notice Regarding Forward-Looking Statements
No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although the Company believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology.
The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, technological obsolescence of the Company's products, technical problems with the Company's research and products, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company's operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company's ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, changes in interest rates, inflationary factors, and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our on going research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration.
There can be no assurance that further research and development, and /or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that PhytoMedical will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Company's most recent Form 10-QSB and Form 10-KSB filings with the Securities and Exchange Commission. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities & Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information about operation of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the U.S. Securities & Exchange Commission at http://www.sec.gov. The Company undertakes no obligation to publicly release the results of any revisions to these forward looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
http://www.PhytoMedical.com
Ultimele PhytoMedical lui anti-cancer de colon uman de compuºi ucide celulele canceroase - PhytoMedical's Latest Anti-Cancer Compounds Kill Human Colon Cancer Cells - articole medicale engleza - startsanatate